A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase IV
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Salmeterol (Primary) ; Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 25 Jun 2018 Status changed from active, no longer recruiting to completed.
- 19 Apr 2018 Planned End Date changed from 18 Jun 2018 to 19 Jun 2018.
- 19 Apr 2018 Planned primary completion date changed from 18 Jun 2018 to 19 Jun 2018.